European patients with advanced EGFR mutation-positive cancer non-small-cell
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive cancer non-small-cell (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive cancer non-small-cell ( EURTAC ) : a multicentre, open-label, randomised phase 3 trial, Lancet Oncol .